Molly Elizabeth Droege
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Molly Elizabeth Droege has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Carolyn Dosen Philpott
Department of Pharmacy, University of Cincinnati Medical Center
4 shared publications - Christopher Allen Droege
Department of Pharmacy Services, UC Health—University of Cincinnati Medical Center, Cincinnati, OH, USA
4 shared publications Eric William Mueller
Department of Pharmacy UC Health – University of Cincinnati Medical Center Cincinnati Ohio USA
3 shared publicationsAmy Teres Makley
Department of Surgery, Division of Trauma University of Cincinnati Cincinnati Ohio USA
2 shared publications- Brian Kramer
Department of Pharmacy Services, OhioHealth/Grant Medical Center, Columbus, OH 43215, USA
2 shared publications Carolyn D. Philpott
Department of Pharmacy Services, UC Health—University of Cincinnati Medical Center, Cincinnati, OH, USA
2 shared publications
Latest Publications
- 22 October 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
A Descriptive Case Series of Pericarditis Treatment After Trauma With Colchicine Monotherapy Versus Other Treatment
Limited data exist describing the optimal treatment of pericarditis after acute blunt or penetrating trauma. Treatment with high-dose nonsteroidal anti-inflammatory drugs (NSAID), colchicine, or corticosteroids may not be feasible due to concomitant injuries. This was a retrospective, single-center, descriptive case series at a large, academic, Level 1 Trauma Center over a 10-year period. Patients admitted to the trauma service with a diagnosis of pericarditis at any point during index admission were eligible for inclusion. Groups were defined as colchicine-based treatment (monotherapy or combination) and any therapy besides colchicine, including no medications (surgical). The primary endpoint was therapy escalation defined as treatment modification, chart note documenting therapy failure, rehospitalization, repeat pericardial surgical intervention, or documentation of recurrent pericarditis. Secondary outcomes were treatment intolerance documented in a chart note including gastrointestinal bleed (GIB) and acute kidney injury (AKI). Eleven patients with traumatic pericarditis were included. Four (36%) patients received colchicine-based therapy: monotherapy (2, [50%]) or combination with NSAID (2, [50%]). Seven (63%) patients received non-colchicine treatment: 2 (29%) NSAID alone; 5 (71%) surgical management without medication. There were no occurrences of therapy escalation in either group. Treatment intolerances occurred in 1 (25%; AKI) patient in the colchicine group and 3 (43%; AKI, 2 [29%], GIB, 1 [14%]) patients in the non-colchicine group. Pericarditis is a rare complication after trauma, and no patients in this case series demonstrated treatment escalation. Additional, larger sample studies are necessary to guide optimal treatment in this uncommon but important population.
- 22 October 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
A Descriptive Case Series of Pericarditis Treatment After Trauma With Colchicine Monotherapy Versus Other Treatment
Limited data exist describing the optimal treatment of pericarditis after acute blunt or penetrating trauma. Treatment with high-dose nonsteroidal anti-inflammatory drugs (NSAID), colchicine, or corticosteroids may not be feasible due to concomitant injuries. This was a retrospective, single-center, descriptive case series at a large, academic, Level 1 Trauma Center over a 10-year period. Patients admitted to the trauma service with a diagnosis of pericarditis at any point during index admission were eligible for inclusion. Groups were defined as colchicine-based treatment (monotherapy or combination) and any therapy besides colchicine, including no medications (surgical). The primary endpoint was therapy escalation defined as treatment modification, chart note documenting therapy failure, rehospitalization, repeat pericardial surgical intervention, or documentation of recurrent pericarditis. Secondary outcomes were treatment intolerance documented in a chart note including gastrointestinal bleed (GIB) and acute kidney injury (AKI). Eleven patients with traumatic pericarditis were included. Four (36%) patients received colchicine-based therapy: monotherapy (2, [50%]) or combination with NSAID (2, [50%]). Seven (63%) patients received non-colchicine treatment: 2 (29%) NSAID alone; 5 (71%) surgical management without medication. There were no occurrences of therapy escalation in either group. Treatment intolerances occurred in 1 (25%; AKI) patient in the colchicine group and 3 (43%; AKI, 2 [29%], GIB, 1 [14%]) patients in the non-colchicine group. Pericarditis is a rare complication after trauma, and no patients in this case series demonstrated treatment escalation. Additional, larger sample studies are necessary to guide optimal treatment in this uncommon but important population.
- 9 October 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (5) , 435-446
Safety Evaluation of Weight-Tiered, Anti-Xa-Guided Versus Fixed-Dose Enoxaparin Prophylaxis in Traumatic IntraCranial Hemorrhage (SAFE-ICH): A Retrospective Cohort Study
Background: Traumatic intracranial hemorrhage (tICH) increases venous thromboembolism (VTE) risk counterbalanced by a life-threatening bleed in a critical organ space. Weight-tiered and anti-Xa-guided enoxaparin dosing may reduce VTE incidence, but current literature is limited regarding safety in patients with tICH. Objective: The purpose of this study was to evaluate the progression of tICH in trauma patients on fixed-dose (FD) versus weight-tiered, anti-Xa-guided enoxaparin for VTE prophylaxis. Methods: This single-center, retrospective study included adult patients admitted to an academic, level 1 trauma center between January 2013 and October 2022. Inclusion criteria were acute tICH and ≥1 prophylactic enoxaparin dose given within 7 days of admission. Groups were FD enoxaparin 30 mg every 12 hours versus weight-tiered, anti-Xa dose-adjusted (DA) enoxaparin per institutional protocols. The primary endpoint was tICH expansion, defined as new or enlarging tICH on computed tomography (CT) or need for neurologic operative intervention within 14 days from chemoprophylaxis initiation. The secondary endpoint compared VTE incidence. A multivariate logistic regression identified risk factors for tICH expansion. Results: A total of 595 patients were included (119 FD; 476 DA). Baseline characteristics were well-matched between groups, including time from stable head CT to chemoprophylaxis initiation. The FD cohort received a lower weight-based dose compared with the DA cohort (0.40 [0.33-0.47] mg/kg/dose vs 0.45 [0.37-0.53] mg/kg/dose, P = 0.001). Traumatic ICH expansion was significantly higher in the FD cohort compared with DA (5 [4.2%] vs 5 [1.1%], P = 0.017). There were similar rates of VTE (2.5% vs 3.6%, P = 0.57) between groups. No independent risk factors were identified for progression of tICH, but higher body mass index was associated with reduced risk. Conclusion and relevance: Higher initial enoxaparin doses and anti-Xa-driven adjustment were not associated with greater rates of tICH expansion in this study, albeit an overall low incidence. These findings highlight the multifactorial nature of TBI and tICH expansion.
- 9 October 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60 (5) , 435-446
Safety Evaluation of Weight-Tiered, Anti-Xa-Guided Versus Fixed-Dose Enoxaparin Prophylaxis in Traumatic IntraCranial Hemorrhage (SAFE-ICH): A Retrospective Cohort Study
Background: Traumatic intracranial hemorrhage (tICH) increases venous thromboembolism (VTE) risk counterbalanced by a life-threatening bleed in a critical organ space. Weight-tiered and anti-Xa-guided enoxaparin dosing may reduce VTE incidence, but current literature is limited regarding safety in patients with tICH. Objective: The purpose of this study was to evaluate the progression of tICH in trauma patients on fixed-dose (FD) versus weight-tiered, anti-Xa-guided enoxaparin for VTE prophylaxis. Methods: This single-center, retrospective study included adult patients admitted to an academic, level 1 trauma center between January 2013 and October 2022. Inclusion criteria were acute tICH and ≥1 prophylactic enoxaparin dose given within 7 days of admission. Groups were FD enoxaparin 30 mg every 12 hours versus weight-tiered, anti-Xa dose-adjusted (DA) enoxaparin per institutional protocols. The primary endpoint was tICH expansion, defined as new or enlarging tICH on computed tomography (CT) or need for neurologic operative intervention within 14 days from chemoprophylaxis initiation. The secondary endpoint compared VTE incidence. A multivariate logistic regression identified risk factors for tICH expansion. Results: A total of 595 patients were included (119 FD; 476 DA). Baseline characteristics were well-matched between groups, including time from stable head CT to chemoprophylaxis initiation. The FD cohort received a lower weight-based dose compared with the DA cohort (0.40 [0.33-0.47] mg/kg/dose vs 0.45 [0.37-0.53] mg/kg/dose, P = 0.001). Traumatic ICH expansion was significantly higher in the FD cohort compared with DA (5 [4.2%] vs 5 [1.1%], P = 0.017). There were similar rates of VTE (2.5% vs 3.6%, P = 0.57) between groups. No independent risk factors were identified for progression of tICH, but higher body mass index was associated with reduced risk. Conclusion and relevance: Higher initial enoxaparin doses and anti-Xa-driven adjustment were not associated with greater rates of tICH expansion in this study, albeit an overall low incidence. These findings highlight the multifactorial nature of TBI and tICH expansion.
- Open Access
- 28 November 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (23) , 3060
Effect of Pharmacoprophylaxis on Postoperative Outcomes in Adult Elective Colorectal Surgery: A Multi-Center Retrospective Cohort Study within an Enhanced Recovery after Surgery Framework
Background: The application of enhanced recovery after surgery principles decreases postoperative complications (POCs), length of stay (LOS), and readmissions. Pharmacoprophylaxis decreases morbidity, but the effect of specific regimens on clinical outcomes is unclear. Methods and Materials: Records of 476 randomly selected adult patients who underwent elective colorectal surgeries (ECRS) at 10 US hospitals were abstracted. Primary outcomes were surgical site infection (SSI), venous thromboembolism (VTE), postoperative nausea and vomiting (PONV), pain, and ileus rates. Secondary outcomes included LOS and 7- and 30-day readmission rates. Results: POC rates were SSI (3.4%), VTE (1.5%), PONV (47.9%), pain (58.1%), and ileus (16.1%). Cefazolin 2 g/metronidazole 500 mg and ertapenem 1 g were associated with the shortest LOS; cefotetan 2 g and cefoxitin 2 g with the longest LOS. No SSI occurred with ertapenem and cefotetan. More Caucasians than Blacks received oral antibiotics before intravenous antibiotics without impact. Enoxaparin 40 mg subcutaneously daily was the most common inpatient and discharge VTE prophylaxis. All in-hospital VTEs occurred with unfractionated heparin. Most received rescue rather than around-the-clock antiemetics. Scopolamine patches, spinal opioids, and IV lidocaine continuous infusion were associated with lower PONV. Transversus abdominis plane block with long-acting local anesthetics, celecoxib, non-anesthetic ketamine bolus, ketorolac IV, lidocaine IV, and pregabalin were associated with lower in-hospital pain severity rates. Gabapentinoids and alvimopan were associated with lower ileus rates. Acetaminophen, alvimopan, famotidine, and lidocaine patches were associated with shorter LOS. Conclusions: Significant differences in pharmacotherapy regimens that may improve primary and secondary outcomes in ECRS were identified. In adult ECRS, cefotetan or ertapenem may be better regimens for preventing in-hospital SSI, while ertapenem or C/M may lead to shorter LOS. The value of OA to prevent SSI was not demonstrated. Inpatient enoxaparin, compared to UFH, may reduce VTE rates with a similar LOS. A minority of patients had a documented PONV risk assessment, and a majority used as-needed rather than around-the-clock strategies. Preoperative scopolamine patches continued postoperatively may lower PONV and PDNV severity and shorter LOS. Alvimopan may reduce ileus and shorten LOS. Anesthesia that includes TAP block, ketorolac IV, and pregabalin use may lead to reduced pain rates. Acetaminophen, alvimopan, famotidine, and lidocaine patches may shorten LOS. Given the challenges of pain management and the incidence of PONV/PDNV found in this study, additional studies should be conducted to determine optimal opioid-free anesthesia and the benefit of newer antiemetics on patient outcomes. Moreover, future research should identify latent pharmacotherapy variables that impact patient outcomes, correlate pertinent laboratory results, and examine the impact of order or care sets used for ECRS at study hospitals.
- 28 November 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (23) , 3060
Open AccessEffect of Pharmacoprophylaxis on Postoperative Outcomes in Adult Elective Colorectal Surgery: A Multi-Center Retrospective Cohort Study within an Enhanced Recovery after Surgery Framework
Background: The application of enhanced recovery after surgery principles decreases postoperative complications (POCs), length of stay (LOS), and readmissions. Pharmacoprophylaxis decreases morbidity, but the effect of specific regimens on clinical outcomes is unclear. Methods and Materials: Records of 476 randomly selected adult patients who underwent elective colorectal surgeries (ECRS) at 10 US hospitals were abstracted. Primary outcomes were surgical site infection (SSI), venous thromboembolism (VTE), postoperative nausea and vomiting (PONV), pain, and ileus rates. Secondary outcomes included LOS and 7- and 30-day readmission rates. Results: POC rates were SSI (3.4%), VTE (1.5%), PONV (47.9%), pain (58.1%), and ileus (16.1%). Cefazolin 2 g/metronidazole 500 mg and ertapenem 1 g were associated with the shortest LOS; cefotetan 2 g and cefoxitin 2 g with the longest LOS. No SSI occurred with ertapenem and cefotetan. More Caucasians than Blacks received oral antibiotics before intravenous antibiotics without impact. Enoxaparin 40 mg subcutaneously daily was the most common inpatient and discharge VTE prophylaxis. All in-hospital VTEs occurred with unfractionated heparin. Most received rescue rather than around-the-clock antiemetics. Scopolamine patches, spinal opioids, and IV lidocaine continuous infusion were associated with lower PONV. Transversus abdominis plane block with long-acting local anesthetics, celecoxib, non-anesthetic ketamine bolus, ketorolac IV, lidocaine IV, and pregabalin were associated with lower in-hospital pain severity rates. Gabapentinoids and alvimopan were associated with lower ileus rates. Acetaminophen, alvimopan, famotidine, and lidocaine patches were associated with shorter LOS. Conclusions: Significant differences in pharmacotherapy regimens that may improve primary and secondary outcomes in ECRS were identified. In adult ECRS, cefotetan or ertapenem may be better regimens for preventing in-hospital SSI, while ertapenem or C/M may lead to shorter LOS. The value of OA to prevent SSI was not demonstrated. Inpatient enoxaparin, compared to UFH, may reduce VTE rates with a similar LOS. A minority of patients had a documented PONV risk assessment, and a majority used as-needed rather than around-the-clock strategies. Preoperative scopolamine patches continued postoperatively may lower PONV and PDNV severity and shorter LOS. Alvimopan may reduce ileus and shorten LOS. Anesthesia that includes TAP block, ketorolac IV, and pregabalin use may lead to reduced pain rates. Acetaminophen, alvimopan, famotidine, and lidocaine patches may shorten LOS. Given the challenges of pain management and the incidence of PONV/PDNV found in this study, additional studies should be conducted to determine optimal opioid-free anesthesia and the benefit of newer antiemetics on patient outcomes. Moreover, future research should identify latent pharmacotherapy variables that impact patient outcomes, correlate pertinent laboratory results, and examine the impact of order or care sets used for ECRS at study hospitals.
- Open Access
- 23 October 2023
- Published by MDPI AG in Preprints.org
Effect of Pharmacoprophylaxis on Postoperative Outcomes in Adult Elective Colorectal Surgery: A Multi-Center Retrospective Cohort Study within an Enhanced Recovery after Surgery Framework
Background: Application of enhanced recovery after surgery principles decrease postoperative complications (POCs), length of stay (LOS), and readmissions. Pharmacoprophylaxis decreases morbidity, but the effect of specific regimens on clinical outcomes is unclear. Methods and Materials: Records of 476 randomly selected adult patients who underwent elective colorectal surgeries (ECRS) at 10 US hospitals were abstracted. Primary outcomes were surgical site infection (SSI), venous thromboembolism (VTE), postoperative nausea and vomiting (PONV), pain, and ileus rates. Secondary outcomes included LOS and 7- and 30-day readmission rates. Results: POC rates were SSI (3.4%), VTE (1.5%), PONV (47.9%), pain (58.1%), and ileus (16.1%). Cefazolin 2g/metronidazole 500mg and ertapenem 1g were associated with the shortest LOS; cefotetan 2g and cefoxitin 2g with the longest LOS. No SSI occurred with ertapenem and cefotetan. More Caucasians than Blacks received oral antibiotics before intravenous antibiotics without impact. Enoxaparin 40 mg subcutaneously daily was the most common inpatient and discharge VTE prophylaxis. All in-hospital VTEs occurred with unfractionated heparin. Most received rescue rather than around the clock antiemetics. Scopolamine patch, spinal opioids, and IV lidocaine continuous infusion were associated with lower PONV. Transversus abdominis plane block with long-acting local anesthetics, celecoxib, non-anesthetic ketamine bolus, ketorolac IV, lidocaine IV, and pregabalin were associated with lower in-hospital pain severity rate. Gabapentinoids and alvimopan were associated with lower ileus rate. Acetaminophen, alvimopan, famotidine, and lidocaine patch were associated with shorter LOS. Conclusions: Significant differences in pharmacotherapy regimens that may improve primary and secondary outcomes in ECRS were identified. Future research should identify latent pharmacotherapy variables that impact patient outcomes.
- 23 October 2023
- Published by MDPI AG in Preprints.org
Open AccessEffect of Pharmacoprophylaxis on Postoperative Outcomes in Adult Elective Colorectal Surgery: A Multi-Center Retrospective Cohort Study within an Enhanced Recovery after Surgery Framework
Background: Application of enhanced recovery after surgery principles decrease postoperative complications (POCs), length of stay (LOS), and readmissions. Pharmacoprophylaxis decreases morbidity, but the effect of specific regimens on clinical outcomes is unclear. Methods and Materials: Records of 476 randomly selected adult patients who underwent elective colorectal surgeries (ECRS) at 10 US hospitals were abstracted. Primary outcomes were surgical site infection (SSI), venous thromboembolism (VTE), postoperative nausea and vomiting (PONV), pain, and ileus rates. Secondary outcomes included LOS and 7- and 30-day readmission rates. Results: POC rates were SSI (3.4%), VTE (1.5%), PONV (47.9%), pain (58.1%), and ileus (16.1%). Cefazolin 2g/metronidazole 500mg and ertapenem 1g were associated with the shortest LOS; cefotetan 2g and cefoxitin 2g with the longest LOS. No SSI occurred with ertapenem and cefotetan. More Caucasians than Blacks received oral antibiotics before intravenous antibiotics without impact. Enoxaparin 40 mg subcutaneously daily was the most common inpatient and discharge VTE prophylaxis. All in-hospital VTEs occurred with unfractionated heparin. Most received rescue rather than around the clock antiemetics. Scopolamine patch, spinal opioids, and IV lidocaine continuous infusion were associated with lower PONV. Transversus abdominis plane block with long-acting local anesthetics, celecoxib, non-anesthetic ketamine bolus, ketorolac IV, lidocaine IV, and pregabalin were associated with lower in-hospital pain severity rate. Gabapentinoids and alvimopan were associated with lower ileus rate. Acetaminophen, alvimopan, famotidine, and lidocaine patch were associated with shorter LOS. Conclusions: Significant differences in pharmacotherapy regimens that may improve primary and secondary outcomes in ECRS were identified. Future research should identify latent pharmacotherapy variables that impact patient outcomes.
- 30 September 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (7) , 705-714
Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury
Background: Drug pharmacokinetics (PK) are altered in neurocritically ill patients, and optimal levetiracetam dosing for seizure prophylaxis is unknown. Objective: This study evaluates levetiracetam PK in critically ill patients with severe traumatic brain injury (sTBI) receiving intravenous levetiracetam 1000 mg every 8 (LEV8) to 12 (LEV12) hours for seizure prophylaxis. Methods: This prospective, open-label study was conducted at a level 1 trauma, academic, quaternary care center. Patients with sTBI receiving seizure prophylaxis with LEV8 or LEV12 were eligible for enrollment. Five sequential, steady-state, postdose serum levetiracetam concentrations were obtained. Non-compartmental analysis (NCA) and compartmental approaches were employed for estimating pharmacokinetic parameters and projecting steady-state trough concentrations. Pharmacokinetic parameters were compared between LEV8 and LEV12 patients. Monte Carlo simulations (MCS) were performed to determine probability of target trough attainment (PTA) of 6 to 20 mg/L. A secondary analysis evaluated PTA for weight-tiered levetiracetam dosing. Results: Ten male patients (5 LEV8; 5 LEV12) were included. The NCA-based systemic clearance and elimination half-life were 5.3 ± 1.2 L/h and 4.8 ± 0.64 hours. A one-compartment model provided a higher steady-state trough concentration for the LEV8 group compared with the LEV12 group (13.7 ± 4.3 mg/L vs 6.3 ± 1.7 mg/L; P = 0.008). Monte Carlo simulations predicted regimens of 500 mg every 6 hours, 1000 mg every 8 hours, and 2000 mg every 12 hours achieved therapeutic target attainment. Weight-tiered dosing regimens achieved therapeutic target attainment using a 75 kg breakpoint. Conclusion and Relevance: Neurocritically ill patients exhibit rapid levetiracetam clearance resulting in a short elimination half-life. Findings of this study suggest regimens of levetiracetam 500 mg every 6 hours, 1000 mg every 8 hours, or 2000 mg every 12 hours may be required for optimal therapeutic target attainment. Patient weight of 75 kg may serve as a breakpoint for weight-guided dosing to optimize levetiracetam therapeutic target attainment for seizure prophylaxis.
- 30 September 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (7) , 705-714
Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury
Background: Drug pharmacokinetics (PK) are altered in neurocritically ill patients, and optimal levetiracetam dosing for seizure prophylaxis is unknown. Objective: This study evaluates levetiracetam PK in critically ill patients with severe traumatic brain injury (sTBI) receiving intravenous levetiracetam 1000 mg every 8 (LEV8) to 12 (LEV12) hours for seizure prophylaxis. Methods: This prospective, open-label study was conducted at a level 1 trauma, academic, quaternary care center. Patients with sTBI receiving seizure prophylaxis with LEV8 or LEV12 were eligible for enrollment. Five sequential, steady-state, postdose serum levetiracetam concentrations were obtained. Non-compartmental analysis (NCA) and compartmental approaches were employed for estimating pharmacokinetic parameters and projecting steady-state trough concentrations. Pharmacokinetic parameters were compared between LEV8 and LEV12 patients. Monte Carlo simulations (MCS) were performed to determine probability of target trough attainment (PTA) of 6 to 20 mg/L. A secondary analysis evaluated PTA for weight-tiered levetiracetam dosing. Results: Ten male patients (5 LEV8; 5 LEV12) were included. The NCA-based systemic clearance and elimination half-life were 5.3 ± 1.2 L/h and 4.8 ± 0.64 hours. A one-compartment model provided a higher steady-state trough concentration for the LEV8 group compared with the LEV12 group (13.7 ± 4.3 mg/L vs 6.3 ± 1.7 mg/L; P = 0.008). Monte Carlo simulations predicted regimens of 500 mg every 6 hours, 1000 mg every 8 hours, and 2000 mg every 12 hours achieved therapeutic target attainment. Weight-tiered dosing regimens achieved therapeutic target attainment using a 75 kg breakpoint. Conclusion and Relevance: Neurocritically ill patients exhibit rapid levetiracetam clearance resulting in a short elimination half-life. Findings of this study suggest regimens of levetiracetam 500 mg every 6 hours, 1000 mg every 8 hours, or 2000 mg every 12 hours may be required for optimal therapeutic target attainment. Patient weight of 75 kg may serve as a breakpoint for weight-guided dosing to optimize levetiracetam therapeutic target attainment for seizure prophylaxis.
- 5 June 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (8) , 870-879
Medication use optimization in critical care through a pharmacy morbidity, mortality, and improvement program
- 5 June 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (8) , 870-879
Medication use optimization in critical care through a pharmacy morbidity, mortality, and improvement program
- Open Access
- 23 September 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (10) , 780-791
Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
Background: Outcomes following andexanet alfa reversal of factor Xa inhibitors in patients requiring urgent or emergent invasive procedures are lacking. This study aimed to describe efficacy and safety outcomes following andexanet alfa administration within 24 h of an invasive procedure.Methods: This single‐center, observational, retrospective study included patients who received andexanet alfa within 24 h of an invasive or surgical procedure. The primary outcome was hemostatic efficacy graded as excellent, good, or poor using similar definitions to the ANNEXA‐4 criteria. Secondary outcomes included hospital discharge disposition, intensive care unit (ICU) and hospital length of stay, 30‐day mortality, 30‐day thromboischemic event rates, and serum coagulation assay changes pre‐ and postreversal.Results: Forty‐four patients met inclusion criteria; of these, 27 (62.8%) received apixaban and 16 (37.2%) were treated with rivaroxaban prior to admission. The indications for reversal were categorized as intracranial (n = 20 [45.5%]) or extracranial (n = 24 [54.5%]) sites. Majority of patients required emergent operative procedures (18 [40.9%]), followed by invasive device placement (10 [22.7%]) or arterial embolization (9 [20.5%]). Thirty‐eight (86.4%) patients were able to be adequately graded for hemostatic efficacy. Overall, 30 (78.9%) patients achieved excellent or good hemostasis within 24 h after periprocedural administration of andexanet alfa (19 [82.6%] apixaban vs. 11 [78.6%] rivaroxaban; 12 [80.0%] intracranial events vs. 18 [78.3%] extracranial events). Discharge disposition was most often to a short‐ or long‐term care facilities (27 [61.4%]). Thirty‐day mortality and thromboischemic complications occurred in 15 (34.1%) and 12 (27.3%) patients, respectively. Prothrombin time and antifactor Xa assay results were significantly decreased after andexanet alfa administration (p < 0.05) while thromboelastogram assay values (reaction time, kinetic time, and activated clotting time) showed nonsignificant changes pre‐ versus postreversal.Conclusion: Andexanet alfa may be used for urgent or emergent reversal of apixaban and rivaroxaban peri‐procedurally with promising hemostatic outcomes. Further prospective, comparative clinical research is warranted.
- 23 September 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (10) , 780-791
Open AccessReversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
Background: Outcomes following andexanet alfa reversal of factor Xa inhibitors in patients requiring urgent or emergent invasive procedures are lacking. This study aimed to describe efficacy and safety outcomes following andexanet alfa administration within 24 h of an invasive procedure.Methods: This single‐center, observational, retrospective study included patients who received andexanet alfa within 24 h of an invasive or surgical procedure. The primary outcome was hemostatic efficacy graded as excellent, good, or poor using similar definitions to the ANNEXA‐4 criteria. Secondary outcomes included hospital discharge disposition, intensive care unit (ICU) and hospital length of stay, 30‐day mortality, 30‐day thromboischemic event rates, and serum coagulation assay changes pre‐ and postreversal.Results: Forty‐four patients met inclusion criteria; of these, 27 (62.8%) received apixaban and 16 (37.2%) were treated with rivaroxaban prior to admission. The indications for reversal were categorized as intracranial (n = 20 [45.5%]) or extracranial (n = 24 [54.5%]) sites. Majority of patients required emergent operative procedures (18 [40.9%]), followed by invasive device placement (10 [22.7%]) or arterial embolization (9 [20.5%]). Thirty‐eight (86.4%) patients were able to be adequately graded for hemostatic efficacy. Overall, 30 (78.9%) patients achieved excellent or good hemostasis within 24 h after periprocedural administration of andexanet alfa (19 [82.6%] apixaban vs. 11 [78.6%] rivaroxaban; 12 [80.0%] intracranial events vs. 18 [78.3%] extracranial events). Discharge disposition was most often to a short‐ or long‐term care facilities (27 [61.4%]). Thirty‐day mortality and thromboischemic complications occurred in 15 (34.1%) and 12 (27.3%) patients, respectively. Prothrombin time and antifactor Xa assay results were significantly decreased after andexanet alfa administration (p < 0.05) while thromboelastogram assay values (reaction time, kinetic time, and activated clotting time) showed nonsignificant changes pre‐ versus postreversal.Conclusion: Andexanet alfa may be used for urgent or emergent reversal of apixaban and rivaroxaban peri‐procedurally with promising hemostatic outcomes. Further prospective, comparative clinical research is warranted.
- 13 September 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (1) , 93-99
Octreotide Dosing in the Medical Management of Chyle Leak Following Otolaryngologic, Thoracic, and Trauma Surgery: A 9-Year Evaluation
Background: Chyle leak is a rare complication following otolaryngologic, thoracic, and trauma surgery wherein the thoracic duct is transected. Case reports and small case series describe octreotide for the medical management of chyle leak, but limited data exist to determine the ideal dose. Objective: To evaluate octreotide dosing in patients with acute chyle leak. Methods: This retrospective, single center, cohort study evaluated adult patients admitted to the otolaryngology, cardiothoracic, and trauma surgery teams over a 9-year period. Patients diagnosed with a chyle leak who received octreotide were eligible for inclusion. Groups were defined as successful medical management or failure requiring definitive surgery. The primary endpoint was daily octreotide dose between groups. Results: Forty-seven patients were included with 29 (61.7%) admitted to the otolaryngology service and 44 (93.6%) with surgical complication as the chyle leak cause. Thirty-two (68.1%) patients had successful medical management while 15 (31.9%) patients failed and required surgical intervention. There was no difference in median daily octreotide dose (250 [IQR, 170-288] µg vs 253 [IQR, 200-282] µg, P = .9). Octreotide weight-based dose, treatment duration, and route of administration were similar between groups. Daily drain output and complete bowel rest were significantly higher in the failure group. Daily drain output was identified as an independent risk factor for failure. Conclusion: Octreotide dose was similar in patients with and without successful medical management of chyle leak. Future studies are needed to determine optimal octreotide dosing and elucidate the relationship between octreotide, drain output, and surgical intervention need.
- 13 September 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (1) , 93-99
Octreotide Dosing in the Medical Management of Chyle Leak Following Otolaryngologic, Thoracic, and Trauma Surgery: A 9-Year Evaluation
Background: Chyle leak is a rare complication following otolaryngologic, thoracic, and trauma surgery wherein the thoracic duct is transected. Case reports and small case series describe octreotide for the medical management of chyle leak, but limited data exist to determine the ideal dose. Objective: To evaluate octreotide dosing in patients with acute chyle leak. Methods: This retrospective, single center, cohort study evaluated adult patients admitted to the otolaryngology, cardiothoracic, and trauma surgery teams over a 9-year period. Patients diagnosed with a chyle leak who received octreotide were eligible for inclusion. Groups were defined as successful medical management or failure requiring definitive surgery. The primary endpoint was daily octreotide dose between groups. Results: Forty-seven patients were included with 29 (61.7%) admitted to the otolaryngology service and 44 (93.6%) with surgical complication as the chyle leak cause. Thirty-two (68.1%) patients had successful medical management while 15 (31.9%) patients failed and required surgical intervention. There was no difference in median daily octreotide dose (250 [IQR, 170-288] µg vs 253 [IQR, 200-282] µg, P = .9). Octreotide weight-based dose, treatment duration, and route of administration were similar between groups. Daily drain output and complete bowel rest were significantly higher in the failure group. Daily drain output was identified as an independent risk factor for failure. Conclusion: Octreotide dose was similar in patients with and without successful medical management of chyle leak. Future studies are needed to determine optimal octreotide dosing and elucidate the relationship between octreotide, drain output, and surgical intervention need.
- 20 February 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (11) , 1222-1230
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
Background: Intrapleural fibrinolytic instillation is second-line treatment for retained hemothorax. Dornase alfa (DNase) has demonstrated efficacy in parapneumonic effusion, but the lack of deoxyribonucleoproteins limits direct extrapolation to traumatic retained hemothorax treatment. Objective: This study evaluated the effectiveness of intrapleural tissue plasminogen activator (tPA) with and without DNase in the treatment of retained traumatic hemothorax. Methods: This retrospective cohort study included patients aged 16 years and older admitted to a level 1 trauma center from January 2013 through July 2019 with retained hemothorax and one or more intrapleural tPA instillations. Exclusion criteria were tPA for other indications or concomitant empyema. The primary endpoint was treatment failure defined as the need for operative intervention. Results: Fifty patients were included (tPA alone: 28; tPA with DNase: 22). Baseline characteristics were similar between groups, including time to diagnosis (6.5 [interquartile range (IQR), 4-15.5] days vs 6 [IQR, 6.3-10.8] days, P = 0.52). Median tPA dose per treatment (6 [IQR, 6-6.4] mg vs 10 [IQR, 8.4-10] mg, P < 0.001) and cumulative tPA (18 [IQR, 6.5-24] mg vs 30 [IQR, 29.5-40], P < 0.001) dose were significantly lower in the tPA alone group. Treatment failure was similar between groups. Chest tube output, retained hemothorax reduction, and bleeding incidences were similar between groups. Multivariate logistic regression demonstrated no significant risk factors for treatment failure. Conclusions and Relevance: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.
- 20 February 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (11) , 1222-1230
Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience
Background: Intrapleural fibrinolytic instillation is second-line treatment for retained hemothorax. Dornase alfa (DNase) has demonstrated efficacy in parapneumonic effusion, but the lack of deoxyribonucleoproteins limits direct extrapolation to traumatic retained hemothorax treatment. Objective: This study evaluated the effectiveness of intrapleural tissue plasminogen activator (tPA) with and without DNase in the treatment of retained traumatic hemothorax. Methods: This retrospective cohort study included patients aged 16 years and older admitted to a level 1 trauma center from January 2013 through July 2019 with retained hemothorax and one or more intrapleural tPA instillations. Exclusion criteria were tPA for other indications or concomitant empyema. The primary endpoint was treatment failure defined as the need for operative intervention. Results: Fifty patients were included (tPA alone: 28; tPA with DNase: 22). Baseline characteristics were similar between groups, including time to diagnosis (6.5 [interquartile range (IQR), 4-15.5] days vs 6 [IQR, 6.3-10.8] days, P = 0.52). Median tPA dose per treatment (6 [IQR, 6-6.4] mg vs 10 [IQR, 8.4-10] mg, P < 0.001) and cumulative tPA (18 [IQR, 6.5-24] mg vs 30 [IQR, 29.5-40], P < 0.001) dose were significantly lower in the tPA alone group. Treatment failure was similar between groups. Chest tube output, retained hemothorax reduction, and bleeding incidences were similar between groups. Multivariate logistic regression demonstrated no significant risk factors for treatment failure. Conclusions and Relevance: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.
- 25 December 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 5 (4) , 428-435
Characterization and evaluation of a pharmacy morbidity, mortality, and improvement case conference for drug safety optimization: An 8‐year experience
Introduction: Traditional morbidity and mortality conferences focus on clinical decision‐making rather than process improvement (PI) and patient safety. A local pharmacy morbidity, mortality, and improvement (MMI) program evolved didactic clinical case presentations into an action‐oriented, resident‐led, case‐based PI learning experience to enhance the institutional patient safety culture.Objectives: The purpose of this report is to describe a pharmacy‐led MMI program including the overall MMI process, characterization of drug errors evaluated, and review of drug use process optimizations.Methods: A narrative review of the MMI process was performed including retrospective characterization of errors and PIs identified from patient safety events presented between June 2013 and August 2021. Errors were classified per the American Society of Health‐System Pharmacists (ASHP) Guidelines on Preventing Medication Errors in Hospitals and the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) Medication Error Index. PI strategies were qualitatively and quantitatively described.Results: Implementation and evolution of MMI over 8 years resulted in consistent error classification, PI interventions across the drug use process, and numerous patient safety continuing education (CE) offerings. Ninety‐seven (80.3%) events completed all MMI components. The majority of events occurred in the emergency department/intensive care unit (42 [43%]) or medical‐surgical floor (36 [37%]). A median of two (interquartile range [IQR] 1‐3) steps in the drug use process contributed to the event. ASHP level 4 (32 [33%]) and NCC MERP category D (22 [21%]) were the most common classifications; NCC MERP error without harm (51 [53%]) had the highest incidence. A total of 163 PI initiatives were identified (median 2 [IQR 1‐2] per case) with 76 (78%) including high‐impact areas such as high‐alert drugs and transitions of care. A total of 606.5 CE hours were awarded.Conclusion: The pharmacy‐led MMI program is an effective and innovative opportunity to enhance patient safety and improve the drug use process.
- 25 December 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 5 (4) , 428-435
Characterization and evaluation of a pharmacy morbidity, mortality, and improvement case conference for drug safety optimization: An 8‐year experience
Introduction: Traditional morbidity and mortality conferences focus on clinical decision‐making rather than process improvement (PI) and patient safety. A local pharmacy morbidity, mortality, and improvement (MMI) program evolved didactic clinical case presentations into an action‐oriented, resident‐led, case‐based PI learning experience to enhance the institutional patient safety culture.Objectives: The purpose of this report is to describe a pharmacy‐led MMI program including the overall MMI process, characterization of drug errors evaluated, and review of drug use process optimizations.Methods: A narrative review of the MMI process was performed including retrospective characterization of errors and PIs identified from patient safety events presented between June 2013 and August 2021. Errors were classified per the American Society of Health‐System Pharmacists (ASHP) Guidelines on Preventing Medication Errors in Hospitals and the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) Medication Error Index. PI strategies were qualitatively and quantitatively described.Results: Implementation and evolution of MMI over 8 years resulted in consistent error classification, PI interventions across the drug use process, and numerous patient safety continuing education (CE) offerings. Ninety‐seven (80.3%) events completed all MMI components. The majority of events occurred in the emergency department/intensive care unit (42 [43%]) or medical‐surgical floor (36 [37%]). A median of two (interquartile range [IQR] 1‐3) steps in the drug use process contributed to the event. ASHP level 4 (32 [33%]) and NCC MERP category D (22 [21%]) were the most common classifications; NCC MERP error without harm (51 [53%]) had the highest incidence. A total of 163 PI initiatives were identified (median 2 [IQR 1‐2] per case) with 76 (78%) including high‐impact areas such as high‐alert drugs and transitions of care. A total of 606.5 CE hours were awarded.Conclusion: The pharmacy‐led MMI program is an effective and innovative opportunity to enhance patient safety and improve the drug use process.